|
Published by: SMI Publishing, Ltd
Published: Jun. 27, 2007
Table of Contents
- Day One
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Jonathan Kingslake, Consultant, PhFolio, formerly Director of Business Integration, Merck, PhFolio Consultants .
- 9.10 TRANSFORMATION FROM A DRUG DELIVERY TO SPECIALTY BIOPHARMACEUTICAL MODEL
- Transformation from a drug delivery to specialty Biopharmaceutical model
- Industry experience regarding the transition from drug delivery to specialty pharmaceuticals, with Nektar Therapeutics as an example of a successful transition.
- Critical Success factors
- Solutions to Overcome Transition Barriers
- Step-By-Step Management of Transition
- Jennifer Filbey , Vice President, Business Development , Nektar Therapeutics.
- 9.50 MAXIMISING PERFORMANCE AND VALUE OF THE DISCOVERY AND EARLY DEVELOPMENT PORTFOLIO
- Optimizing the portfolio to deliver the company’s strategic objectives
- Balancing the level of investment with the level of risk
- Managing the program not just the individual projects
- Enabling effective and timely decision making
- Jonathan Kingslake, Consultant, PhFolio, formerly Director of Business Integration, Merck, PhFolio Consultants .
- 10.30 Morning Coffee
- 11.30 MAXIMIZING PROFITABILITY THROUGH INTEGRATION OF LIFE CYCLE AND PORTFOLIO MANAGEMENT
- Linking Life Cycle and Portfolio Management with Corporate Strategy
- Pharmaceutical companies must continuously develop new drugs to the market
- The challenge is managing the portfolio to reduce time-to-market and maximize return on investment
- Effective product development comprises two components: Optimal Life Cycle Management and having right products in your portfolio
- Integration of results is an added value: enabling companies to proactively manage the portfolio by proactively having key information at multiple levels
- A link with strategic objectives enables you to measure the alignment of projects in the portfolio with corporate strategy
- These benefits should result in a reduction of time-to-market with improved quality to maximize profitability
- Hans Hoogkamer , Head, Lifecycle Portfolio Alignment, Actelion Pharmaceuticals .
- 12.10 THE IMPORTANCE OF SUPPLEMENTARY PROTECTION CERTIFICATES IN LIFE CYCLE MANAGEMENT
- Recent developments: from AstraZeneca to MIT and Yissum
- The unique nature of SPCs
- Recent rulings from the European Court of Justice
- The European Commission’s decision on the AstraZeneca case
- Assessing the importance of SPCs
- Duncan Curley , Director, Innovate Legal .
- 12.50 Networking Lunch
- 1.50 PATENT ENFORCEMENT IN EUROPE
- How to litigate in a union of 27
- Nigel Stoate, Partner, Taylor Wessing.
- 2.30 LICENSING AS A LIFE CYCLE MANAGEMENT TOOL
- Key issues when licensing a marketed product
- Specific due diligence issues
- Dealing with specialty pharma
- Alternatives to licensing
- John Wilkinson, Partner and Co-Head,, Reed Smith LLP.
- 3.10 Afternoon Tea
- 3.40 DEVELOPING STRATEGIES FOR PROTECTING IP POTENTIAL IN BIOTECH AND PHARMACEUTICAL INVENTIONS
- Patenting, partnering and pursuing extended profitability for existing products
- Strategies for protecting IP potential: the legal and regulatory framework
- Protectable subject matter: beyond basic compound strategies
- Prosecution strategies: what to file when?
- “Offensive” enforcement strategies: where to sue when?
- “Defensive” strategies
- Stephen Bennett, Partner, Lovells.
- 4.20 MARKET ACCESS FOCUS FOR COMMERCIALISATION
- Project selection by assessment of health gain
- Market valuation using curve analysis Pricing and reimbursement strategy
- Local formulary dossier creation and listing
- Brian Lovatt, Chief Executive Officer & Managing Director, Vision Healthcare .
- 5.00 Chairman’s Closing Remarks and Close of Day One
- Day two
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Marjan Noor, Partner, Taylor Joynson Garrett.
- 9.10 DEVELOPING A SPECIALITY PHARMA PORTFOLIO
- Deciding on the balance
- Becoming a favoured partner
- Turning ideas into products
- Getting the financing right
- Delivering shareholder value
- John Dawson, Chief Executive Officer, Alliance Pharmaceuticals.
- 9.50 TRANSFORMING OPERATIONS THROUGH IMPLEMENTATION OF VALUE-DRIVEN CONCEPTS
- Improving development of compounds to viable drugs
- Reviewing procedures to identify bottlenecks and overspending
- Structural changes improving functionality at discovery, development and commercial interfaces
- Delivering the value proposition through improved pipeline flow through and late stage success
- Dr Sabine Bernotat-Danielowski, Executive Director, Decision Analysis, Daiichi-Sankyo.
- 10.30 Morning Coffee
- 11.00 PRODUCT LIFECYCLE MANAGEMENT
- Analysis of Recent Case Law
- Outsourcing lead finding and early development to partnering companies with novel technologies
- Extending knowledge gathering beyond existing in-house capabilities
- Gauging the value of a partnership beyond the scope of the deal
- Allistair Booth, Partner, Stringer Saul.
- 11.40 PORTFOLIO RISK MANAGEMENT & OPTIMISATION IN PHARMA R&D
- Reducing attrition and addressing the productivity challenges facing the industry
- Productivity (in terms of new NME launches) has dropped off considerably in the last few years
- R&D spend has continued to escalate
- Much hyped technologies such as genomics, HTS have failed to deliver productivity improvements
- Portfolio Risk-Management has been sub-optimal within the industry
- New operating models and better understanding of human disease processes need to be applied to address these productivity challenges
- Tools, methods and novel paradigms to improve productivity
- Dr Harsukh Parmer, Director, Global Discovery Medicine, Respiratory & Inflammation Therapy, AstraZeneca.
- 12.20 Networking Lunch
- 1.50 COMMERCIAL PORTFOLIO STRATEGY
- Optimising decision-making in future planning for pharmaceutical portfolios
- Best practice in pharmaceutical and consumer portfolio planning
- The commercial imperative and the customer construct
- Integrating commercial and technical risk analyses
- Managing multiple brands in the same indication
- Future mapping and future proofing
- Mike Rea, Chief Executive Officer, IdeaPharma.
- 2.30 PATENT FILING STRATEGIES AS A DEFENCE AGAINST GENERIC COMPETITION
- Importance of Patents as a Lifecycle Management Strategy
- Drug patent filing trends - past and present
- Timing of patent filings for optimal benefit
- The future of patents as a viable defence strategy
- Leighton Howard , Managing Director, Generics Web.
- 3.10 Afternoon Tea
- 3.40 QUANTIFYING THE KEY VALUE DRIVERS FOR DEVELOPMENT COMPOUNDS AND LIFE CYCLE MANAGEMENT INITIATIVES
- Identifying development opportunities by focusing on the 'vital few' drivers of commercial value
- Drivers of pricing leverage: quantifying and valuing clinical benefit, payer sensitivity etc. to each opportunity
- Drivers of market penetration: quantifying the impact of profile, entry order etc. on market penetration
- Drivers of market growth: identifying the proven markers of market expansion - increased diagnosis and prescription
- Drivers of uptake rate: which opportunities will obtain market penetration fastest to deliver greater NPVs
- Gary Johnson, Managing Director, Inpharmation.
- 4.20 SCENARIO PLANNING FOR STRATEGIC PORTFOLIO DEVELOPMENT
- Developing a Sustainable Portfolio through Scenario Planning
- Scenarios as strategic drivers for change
- Why scenarios will be critical in the healthcare arena
- Keith Rodgers, Director, Bodiam Consulting.
- 5.00 Chairman’s Closing Remarks and Close of Day Two
AbstractBranded pharmaceutical companies face soaring costs of R&D, shrinking pipelines and increased generics competition. In response, questions are raised as to the sustainability of traditional business models, and the leading companies are reviewing their working practices to better mange assets and resources:
- Transforming operations to improve the development of compounds to drugs
- Maximizing profitability through integration of lifecycle and portfolio management
- Shaping business development through collaborative ventures
- Adapting IP protection to lifecycle stages
The SMi Group’s 2nd Annual Pharmaceutical Portfolio & Lifecycle Management Conference brings together Vice Presidents, Directors and Heads from the pharmaceutical industry to discuss the critical issues surrounding the development of innovative drugs and maintenance of existing assets.
Hear contributions from leading industry experts, including:
- Dr Hoyoung Huh, Senior Vice President, Business Development & Marketing, Nektar Therapeutics
- Dr Alan Norris, Director, Strategic Alliances, Gastrointestinal Disease Area, Novartis
- Dr Sabine Bernotat-Danielowski, Executive Director, Decision Analysis, Daiichi-Sankyo
- Dr Harsukh Parmer, Director, Global Discovery Medicine, Respiratory & Inflammation Therapy, AstraZeneca
- Sandy K Tremps, Director, PreClinical Information Services, Merck
- Dr Alan Raymond, Executive Chairman, Critical Pharmaceuticals
- Hans Hoogkamer, Head, Life Cycle Portfolio Alignment, Actelion Pharmaceuticals
- Mike Rea, Chief Executive Officer, IdeaPharma
The SMi Group’s 2nd Annual Pharmaceutical Portfolio & Lifecycle Management Conference provides a unique opportunity to participate in a lively debate and profit from the wealth of knowledge and expertise shared.
Designed to meet industry needs, the conference creates the perfect setting for prolific exchanges of ideas and networking opportunities.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
